CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $1.5M, lower than 95% of all stocks globally
- PositionCurrent ratio is 0.08×, lower than 95% of its Biotechnology peers (median 5.64×)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
271.15MUSDvs all stocks (USD)
Revenue (TTM)
1.50MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
-0.6260xvs all stocks
52-Week Change
-32.00%vs all stocks
Market Capitalization
271.15MUSDvs all stocks (USD)
Enterprise Value
351.96MUSDvs all stocks (USD)
Forward P/E
-2.43xvs Biotechnology peers
Enterprise to Revenue
235.11xvs Biotechnology peers
Enterprise to EBITDA
-6.89xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-2206.48%vs Biotechnology peers
Return on Assets (TTM)
-62.18%vs Biotechnology peers
Revenue (TTM)
1.50MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.0010USDUpdated Jul 19, 2026Quarterly Revenue Growth
31.70%vs Biotechnology peers
Gross Profit (TTM)
-23.80MUSDvs all stocks (USD)
EBITDA (TTM)
-51.10MUSDvs all stocks (USD)
Net Income (TTM)
-45.27MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
31.73%vs Biotechnology peers
Operating Cash Flow (TTM)
-47.85MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-36.92MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
1.38MUSDFY2025 · Dec 31, 2025Operating Income
-59.91MUSDvs all stocks (USD)
Pre-tax Income
-60.70MUSDFY2025 · Dec 31, 2025Income Tax Expense
-537.00KUSDFY2025 · Dec 31, 2025Net Income
-60.16MUSDFY2025 · Dec 31, 2025EBIT
-52.00MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-62.67MUSDFY2025 · Dec 31, 2025Research & Development
28.79MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
32.51MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
8.70MUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.0400USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.0400USDFY2025 · Dec 31, 2025Basic Shares Outstanding
1.46BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
1.46BSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-60.16MUSDFY2025 · Dec 31, 2025Preferred Stock Dividends
1.31MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-35.84MUSDFY2025 · Dec 31, 2025Free Cash Flow
-37.34MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
3.04MUSDFY2025 · Dec 31, 2025Interest Paid
388.00KUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-60.16MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
2.34MUSDFY2025 · Dec 31, 2025Stock-based Compensation
1.21MUSDFY2025 · Dec 31, 2025Other Non-cash Items
6.98MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
13.69MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
108.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-1.50MUSDFY2025 · Dec 31, 2025Other Investing Activity
-311.00KUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-1.81MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
31.25MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-1.27MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
49.30MUSDFY2025 · Dec 31, 2025Shares Outstanding
1.61BSharesUpdated Jul 19, 2026Float Shares
1.61BSharesUpdated Jul 19, 2026Shares Short
14.14MSharesUpdated Jul 19, 2026Short Ratio
13.54daysvs all stocks
Short % of Shares Outstanding
15.09%vs all stocks
% Held by Insiders
4.26%vs all stocks
% Held by Institutions
0.06%vs all stocks
Total Cash (MRQ)
1.79MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.0010USDUpdated Jul 19, 2026Total Debt (MRQ)
63.99MUSDvs all stocks (USD)
Current Ratio (MRQ)
0.0750xvs Biotechnology peers
Book Value per Share (MRQ)
-0.0310USDUpdated Jul 19, 2026Total Assets
81.29MUSDvs all stocks (USD)
Total Current Assets
5.52MUSDFY2025 · Dec 31, 2025Total Liabilities
141.57MUSDFY2025 · Dec 31, 2025Total Non-current Assets
75.77MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
49.87MUSDFY2025 · Dec 31, 2025Total Current Liabilities
91.70MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
3.04MUSDFY2025 · Dec 31, 2025Accounts Payable
30.82MUSDFY2025 · Dec 31, 2025Short-term Debt
42.54MUSDFY2025 · Dec 31, 2025Other Current Liabilities
207.00KUSDFY2025 · Dec 31, 2025Long-term Debt
22.29MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
1.70MUSDFY2025 · Dec 31, 2025Common Stock (Book)
1.57MUSDFY2025 · Dec 31, 2025Retained Earnings
-1.50BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
-60.28MUSDvs all stocks (USD)
Treasury Stock
12.00KUSDFY2025 · Dec 31, 202552-Week Low
0.1400USDUpdated Jul 19, 202652-Week High
0.3700USDUpdated Jul 19, 202652-Week Change
-32.00%vs all stocks
Beta
-0.6260xvs all stocks
50-Day MA
0.2046USDUpdated Jul 19, 2026200-Day MA
0.2291USDUpdated Jul 19, 2026Avg 10-Day Volume
4.67MSharesUpdated Jul 19, 2026Avg 30-Day Volume
3.39MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-0.0300USDUpdated Jul 19, 2026Other Income / Expense
7.91MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 0.08×, lower than 95% of its Biotechnology peers (median 5.64×)Significant
Current ratio: 0.07Industry median: 5.64Industry P5: 1.06Peers compared: 261
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.56
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $1.5M, lower than 95% of all stocks globallySignificant
Revenue (USD): 1,497,000Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Sab Biotherapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Opus Genetics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
United Orthopedic Corporation
Tier 1ProductionApproval-Gated PipelineRule
Oryzon Genomics S.A.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Curocell Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Entrada Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
PharmaEngine, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Senseonics Holdings, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Ginwa Enterprise Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cresco Labs Inc.
Tier 1ProductionApproval-Gated PipelineFlowRule
Companies that share active interpretations — structural patterns currently present in both stocks.
A2Z Cust2Mate Solutions Corp
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Beam Therapeutics Inc.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Wave Life Sciences Ltd.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC